Currently, there are 386.00M common shares owned by the public and among those 341.66M shares have been available to trade.
The company’s stock has a 5-day price change of 0.15% and -21.04% over the past three months. MRNA shares are trading -18.69% year to date (YTD), with the 12-month market performance down to -67.32% lower. It has a 12-month low price of $29.25 and touched a high of $170.47 over the same period. MRNA has an average intraday trading volume of 11.77 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.04%, -5.96%, and -50.74% respectively.
Institutional ownership of Moderna Inc (NASDAQ: MRNA) shares accounts for 70.79% of the company’s 386.00M shares outstanding.
It has a market capitalization of $13.04B and a beta (3y monthly) value of 2.16. The earnings-per-share (ttm) stands at -$9.28. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.78% over the week and 7.44% over the month.
Earnings per share for the fiscal year are expected to decrease by -8.81%, and 22.59% over the next financial year. EPS should grow at an annualized rate of 14.68% over the next five years, compared to -42.94% over the past 5-year period.
Looking at the support for the MRNA, a number of firms have released research notes about the stock. Citigroup stated their Neutral rating for the stock in a research note on March 13, 2025, with the firm’s price target at $40. Barclays coverage for the Moderna Inc (MRNA) stock in a research note released on February 18, 2025 offered a Equal Weight rating with a price target of $45. BofA Securities on their part issued Underperform rating on December 10, 2024.
